05
May
Remedium Lifecare Limited (BSE: 539561) has launched its ₹49.19 crore Rights Issue, which will open on April 30 and close on May 14, 2025. The move follows the Bombay Stock Exchange's approval and is aimed at bolstering the company’s transformation into a vertically integrated, research-led global pharmaceutical player. The capital raise aligns with Remedium's recent ₹182.7 crore deal with a UK-based pharma company and will be directed towards boosting working capital, scaling R&D and production, digital transformation, and attracting top talent. A significant portion will go into setting up advanced research labs focused on CNS disorders, metabolic diseases, and oncology.…
